A 48-week, multinational, multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase III extension study to evaluate the treatment response and safety of two dosage regimens of amlitelimab administered as monotherapy by subcutaneous injection in participants 12 years of age and older with moderate to severe atopic dermatitis.